Audentes Therapeutics Inc at the ARM 5th Annual Cell & Gene Therapy Investor Day (Live)
04/27/17 at 9:55 a.m. ET
We currently have four products in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Type 1, AT307 for the treatment of CASQ2-related Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), and AT982 for the treatment of Pompe disease.
|Recent News||More >>|
|Upcoming Events||More >>|
|Primary IR Contact|
SVP and Chief Financial Officer
Audentes Therapeutics, Inc.
Data provided by Nasdaq. Minimum 15 minutes delayed.